

Humira and Biosimilars (adalimumab)
Effective 08/16/2026

Plan	☐ MassHealth UPPL ☒ Commercial/Exchange	Program Type	☒ Prior Authorization
Benefit	☒ Pharmacy Benefit ☐ Medical Benefit		☐ Quantity Limit ☐ Step Therapy
Specialty Limitations	This medication has been designated specialty and must be filled at a contracted specialty pharmacy.		
Contact Information	Medical Benefit Pharmacy Benefit	Phone: 833-895-2611 Phone: 800-711-4555	Fax: 888-656-6671 Fax: 844-403-1029
Exceptions	N/A		

Overview

Adalimumab is a recombinant monoclonal antibody that binds to human tumor necrosis factor alpha (TNF-alpha), thereby interfering with binding to TNF α receptor sites and subsequent cytokine-driven inflammatory processes.

Preferred	Non-Preferred
Humira (Abbvie)	Amjevita (Amgen)
Hadlima	Amjevita (Nuvaia)
Simlandi	Adalimumab-aaty
Yuflyma	Adalimumab-aacf
	Adalimumab-adbm
	Adalimumab-bwwd
	Adalimumab-ryvk
	Adalimumab-adaz
	Adalimumab-fkjp
	Cyltezo
	Hyrimoz
	Abrilada
	Hulio
	Humira (Cordavis)
	Idacio
	Yusimry

Coverage Guidelines

If member is new to the plan (as evidenced by coverage effective date of less than or equal to 90 days), submission of medical records documenting that the member is currently receiving treatment with the requested drug, excluding when the product is obtained as samples or via manufacturer's patient assistance programs

OR

Authorizations may be granted for members who meet all of the following diagnosis-specific criteria:

Moderately to severely active rheumatoid arthritis (RA)

1. Diagnosis of moderately to severely active rheumatoid arthritis (RA)
2. Minimum duration of 3-month trial and failure, contraindication, or intolerance to ONE of the following conventional therapies at maximally tolerated doses:
 - a. Methotrexate
 - b. Leflunomide
 - c. Sulfasalazine
3. **Nonpreferred Adalimumab Products:** Trial and failure, contraindication, or intolerance to TWO of the following:
 - a. Humira (Abbvie)
 - b. Hadlima
 - c. Simlandi
 - d. Yuflyma

Moderately to severely active polyarticular juvenile idiopathic arthritis (pJIA)

1. Diagnosis of moderately to severely active polyarticular juvenile idiopathic arthritis (pJIA)
2. Minimum duration of 6-week trial and failure, contraindication, or intolerance to ONE of the following conventional therapies at maximally tolerated doses:
 - a. Leflunomide
 - b. Methotrexate
3. **Nonpreferred Adalimumab Products:** Trial and failure, contraindication, or intolerance to TWO of the following:
 - a. Humira (Abbvie)
 - b. Hadlima
 - c. Simlandi
 - d. Yuflyma

Active psoriatic arthritis (PsA)

1. Diagnosis of active psoriatic arthritis
2. ONE of the following:
 - a. Actively inflamed joints
 - b. Dactylitis
 - c. Enthesitis
 - d. Axial disease
 - e. Active skin and/or nail involvement
3. **Nonpreferred Adalimumab Products:** Trial and failure, contraindication, or intolerance to TWO of the following:
 - a. Humira (Abbvie)
 - b. Hadlima
 - c. Simlandi
 - d. Yuflyma

Active ankylosing spondylitis (AS)

1. Diagnosis of active ankylosing spondylitis
2. Minimum duration of 1-month trial and failure, contraindication, or intolerance to TWO different non-steroidal anti-inflammatory drugs (NSAIDs) (e.g., ibuprofen, naproxen) at maximally tolerated doses.
3. **Nonpreferred Adalimumab Products:** Trial and failure, contraindication, or intolerance to TWO of the following:



- a. Humira (Abbvie)
- b. Hadlima
- c. Simlandi
- d. Yuflyma

Moderately to Severely Active Crohn's Disease (CD)

1. Diagnosis of the moderately to severely active Crohn's disease (CD)
2. ONE of the following:
 - a. Trial and failure, contraindication, or intolerance to ONE of the following conventional therapies:
 - i. 6-mercaptopurine
 - ii. Azathioprine
 - iii. Corticosteroids (e.g., prednisone)
 - iv. Methotrexate
 - b. Disease severity warrants systemic biologic or targeted synthetic therapy as first-line therapy
3. **Nonpreferred Adalimumab Products:** Trial and failure, contraindication, or intolerance to TWO of the following:
 - a. Humira (Abbvie)
 - b. Hadlima
 - c. Simlandi
 - d. Yuflyma

Moderately to severely active ulcerative colitis (UC)

1. Diagnosis of moderately to severely active ulcerative colitis
2. ONE of the following:
 - a. Trial and failure, contraindication, or intolerance to ONE of the following conventional therapies:
 - i. 6-mercaptopurine
 - ii. Aminosalicylate (e.g., mesalamine, olsalazine, sulfasalazine)
 - iii. Azathioprine
 - iv. Corticosteroids (e.g., prednisone)
 - b. Disease severity warrants systemic biologic or targeted synthetic therapy as first-line therapy
3. **Nonpreferred Adalimumab Products:** Trial and failure, contraindication, or intolerance to TWO of the following:
 - a. Humira (Abbvie)
 - b. Hadlima
 - c. Simlandi
 - d. Yuflyma

Moderate to severe chronic plaque psoriasis (PsO)

1. Diagnosis of moderate to severe chronic plaque psoriasis
2. At least 3% of body surface area (BSA) is affected OR crucial body areas (e.g., hands, feet, face, neck, scalp, genitals/groin, intertriginous areas) are affected
3. Member meets ONE of the following criteria:
 - a. Minimum duration of 4-week trial and failure, contraindication, or intolerance to ONE of the following topical therapies:
 - i. Corticosteroids (e.g., betamethasone, clobetasol)
 - ii. Vitamin D analogs (e.g., calcitriol, calcipotriene)
 - iii. Tazarotene
 - iv. Calcineurin inhibitors (e.g., tacrolimus, pimecrolimus)



- v. Anthralin
 - vi. Coal tar
 - b. Member has severe psoriasis that warrants a biologic DMARD or targeted synthetic therapy as first-line therapy.
4. **Nonpreferred Adalimumab Products:** Trial and failure, intolerance, or contraindication to TWO of the following:
- a. Humira (Abbvie)
 - b. Hadlima
 - c. Simlandi
 - d. Yuflyma

Moderate to severe hidradenitis suppurativa

- 1. Diagnosis of moderate to severe hidradenitis suppurativa (Hurley stage II or III)
- 2. **Nonpreferred Adalimumab Products:** Trial and failure, contraindication, or intolerance to TWO of the following:
 - a. Humira (Abbvie)
 - b. Hadlima
 - c. Simlandi
 - d. Yuflyma

Non-infectious Uveitis

- 1. Diagnosis of non-infectious uveitis
- 2. Uveitis is classified as ONE of the following:
 - a. Intermediate
 - b. Posterior
 - c. Panuveitis
- 3. **Nonpreferred Adalimumab Products:** Trial and failure, contraindication, or intolerance to TWO of the following:
 - a. Humira (Abbvie)
 - b. Hadlima
 - c. Simlandi
 - d. Yuflyma

Continuation of Therapy

Requests for reauthorization for all diagnoses will be approved when the following criteria are met:

- 1. Submission of medical records (e.g., chart notes) documenting an improvement in the member's condition, as evidenced by low disease activity or improvement in signs and symptoms of the condition.

Limitations

- 1. Initial approval and reauthorizations will be granted for 24 months
- 2. The following quantity limits apply:

Dosage	Quantity Limit
Starter Packs	1 pack per 365 days
10 mg injection	2 injections per 28 days
20 mg injection	4 injections per 28 days
40 mg injection	4 injections per 28 days
80 mg injection	2 injections per 28 days



References

1. Beukelman T, Patkar NM, Saag KG, et al. 2011 American College of Rheumatology recommendations for the treatment of juvenile idiopathic arthritis: initiation and safety monitoring of therapeutic agents for the treatment of arthritis and systemic features. *Arthritis Care Res.* 2011;63(4):465-482.
2. Braun J, van den Berg R, Baraliakos X, et al. 2010 update of the ASAS/EULAR recommendations for the management of ankylosing spondylitis. *Ann Rheum Dis* 2011; 70:896–904.
3. Gladman DD, Antoni C, P Mease, et al. Psoriatic arthritis: epidemiology, clinical features, course, and outcome. *Ann Rheum Dis* 2005;64(Suppl II): ii14–ii17.
4. Gossec L, Smolen JS, Ramiro S, et al. European League Against Rheumatism (EULAR) recommendations for the management of psoriatic arthritis with pharmacological therapies; 2015 update. *Ann Rheum Dis.* 2016;75(3):499-510.
5. Humira (adalimumab) [prescribing information]. North Chicago, IL: AbbVie Inc; February 2024.
6. Jaffe GJ, Dick AD, Brézín AP, et al. Adalimumab in Patients with Active Noninfectious Uveitis. *N Engl J Med* 2016; 375:932
7. Landewé R, Sieper J, Mease P, et al. Efficacy and safety of continuing versus withdrawing adalimumab therapy in maintaining remission in patients with non-radiographic axial spondyloarthritis (ABILITY-3): a multicentre, randomised, double-blind study. *Lancet* 2018; 392:134
8. Saag KG, Teng GG, Patkar NM, et al. American College of Rheumatology 2008 recommendations for the use of nonbiologic and biologic disease-modifying antirheumatic drugs in rheumatoid arthritis. *Arthritis Rheum.* 2008;59(6):762-784.
9. Singh JA, Saag KG, Bridges SL Jr, et al. 2015 American College of Rheumatology Guideline for the Treatment of Rheumatoid Arthritis. *Arthritis Rheumatol.* 2016;68(1)1-26.
10. Smolen JS, Landewé R, Billsma J, et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2016 update. *Ann Rheum Dis.* 2017; 0:1-18.
11. Talley NJ, Abreu MT, Achkar J, et al. An evidence-based systematic review on medical therapies for inflammatory bowel disease. *Am J Gastroenterol.* 2011;106(Suppl 1): S2-S25.
12. van der Heijde D, Ramiro S, Landewe R, et al. 2016 Update of the international ASAS-EULAR management recommendations for axial spondyloarthritis. *Ann Rheum Dis.* 2017;0:1-14.
13. Zouboulis CC, Okun MM, Prens EP, et al. Long-term adalimumab efficacy in patients with moderate-to-severe hidradenitis suppurativa/acne inversa: 3-year results of a phase 3 open-label extension study. *J Am Acad Dermatol* 2019; 80:60

Review History

03/21/2005 – Reviewed

05/15/2005 – Effective

02/27/2006 – Reviewed and revised

02/25/2008 – Reviewed and revised

02/23/2009 – Reviewed and revised

02/22/2010 – Reviewed and revised

02/28/2011 – Reviewed in P&T Meeting

02/27/2012 – Reviewed and revised

02/25/2013 – Reviewed and revised

02/24/2014 – Reviewed and revised

02/23/2015 – Reviewed and revised

02/22/2016 – Reviewed and revised

02/2017 – Reviewed and revised (switched to SGM)



02/26/2018 – Reviewed and revised

11/26/2018 – Reviewed and revised (switched to Custom) in P&T Meeting

07/22/2020 – Reviewed and updated July P&T Mtg; reworded overview; changed diagnosis of axial spondyloarthritis to nonradiographic axial spondyloarthritis; updated references. Effective 10/01/2020.

11/15/2023 – Reviewed and Updated for Nov P&T; removed TB requirement. Added additional treatment options for conventional therapies for Rheumatoid arthritis. Added additional treatment options for 6-week treatment for PJIA. Psoriatic arthritis – removed conventional therapies and added member meets one of the following: actively inflamed joints, dactylitis, enthesitis, axial disease, or active skin and/or nail involvement. Plaque psoriasis – changed from 5% BSA to 3% BSA. Removed appendix with contraindications to methotrexate. Consolidated conventional therapies for plaque psoriasis. Removed conventional therapy for uveitis. Added preferred agents: Humira, Hadlima, Adalimumab-adaz, and Adalimumab-fkjp. Non-preferred agents require prior use of TWO preferred agents. Effective 1/1/24

3/13/2024 – Reviewed and Updated for March P&T; Added Humira (Cordavis manufacturer) as a non-preferred agent. Criteria reflects Humira (Abbvie manufacturer) is preferred. Effective ASAP

08/14/2024 – Reviewed and updated for August P&T. Added adalimumab-aaty, adalimumab-adbm, adalimumab-ryvk, and Simlandi as non-preferred agents. Clarified step therapy language to indicate member must be new to the plan within the past 90 days. Effective 10/1/2024.

10/9/2024 – Reviewed and updated for October P&T. Added Amjevita (Nuvaila) as a preferred adalimumab product. Specified that Amjevita (Amgen) is nonpreferred. Updated policy to include Amjevita (Nuvaila) as a preferred adalimumab step therapy option. Effective 1/1/2025.

11/13/2024 – Reviewed and updated for November P&T. Added adalimumab-aacf as a nonpreferred product. Effective 02/01/2025.

12/11/2024 – Reviewed and updated for December P&T. Removed diagnosis of nonradiographic axial spondyloarthritis. Effective 3/1/2025.

05/14/2025 – Reviewed and updated for May P&T. Updated criteria for Crohn's disease and ulcerative colitis to remove disease characteristic requirement and allow for approval if disease severity warrants systemic biologic as first-line therapy. Effective 07/01/2025.

10/08/2025 – Reviewed and updated for October P&T. Updated verbiage for nonpreferred agents and trial language for ankylosing spondylitis. Updated policy to reflect updated preferred adalimumab products. Effective 01/01/2026.

11/12/2025 – Reviewed and updated for November P&T. Administrative update – added quantity limits to the policy. Effective 01/01/2026.

03/11/2026 – Reviewed and updated for March P&T. Effective 04/01/2026: administrative update - changing verbiage in reauthorization criteria from “documentation is submitted” to “submission of medical records (e.g., chart notes...” and updating language for members who are new to the Plan. Effective 05/01/2025: Adding adalimumab-bwwd to the policy as a nonpreferred adalimumab product. Administrative update made to remove examples of nonpreferred adalimumab products throughout the criteria and instead replaced with “nonpreferred adalimumab products.”

04/15/2026 – Reviewed and updated at April P&T. Updated previous trial language for plaque psoriasis, ulcerative colitis and Crohn's disease, allowing for bypassing conventional therapy if member has severe psoriasis that warrants a systemic biologic or targeted synthetic therapy as first-line therapy. Effective 08/16/2026.

